Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
BUSINESS
Moderna Files Omicron Bivalent Vaccine in Japan
Moderna has filed its Omicron-containing bivalent COVID-19 vaccine in Japan as a booster candidate for use in people aged 18 and older, the company said on August 10. The vaccine is expected to be reviewed in the special approval pathway,…
To read the full story
Related Article
- Moderna Files BA.4/5-Tailored COVID-19 Vaccine in Japan
October 5, 2022
- Japan OKs Omicron COVID-19 Vaccines from Pfizer, Moderna
September 13, 2022
- Pfizer/Moderna’s Omicron Vaccines on Japan Panel Agenda on Sept. 12
September 8, 2022
- Moderna to File BA.4/5-Targeting Booster Jab in Japan
September 6, 2022
- Japan Govt to Start Omicron Vaccine Distribution from Week of Sept. 19
September 6, 2022
- Japan to Give Omicron Boosters to Elderly from Mid-September
September 5, 2022
- Japan Mulls Moving Up Omicron Boosters to September
August 31, 2022
- Japan to Begin BA.1-Based Omicron Booster Program as Early as October
August 9, 2022
- Pfizer Seeks Japan Nod for Omicron-Adapted Bivalent Jab
August 9, 2022
- Moderna Eyes Bivalent Booster Rollout This Fall via Emergency Approval Path in Japan: CMO
May 30, 2022
BUSINESS
- Quviviq Tops Sales Rep Call Ranking for GPs in February: Intage
April 4, 2025
- Merck Biopharma to Develop PharmaMar’s SCLC Drug in Japan
April 4, 2025
- Jump in New Grad Hires Seen with Drug Makers in Japan: 2025 Poll
April 4, 2025
- Susaki City to Subsidize Beyfortus Use in Healthy Babies
April 3, 2025
- Ultomiris, Soliris Bolster Labels for gMG in Japan: Alexion
April 3, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…